

McDermott
Will&Emery

RECEIVED
CENTRAL FAX CENTER
JUN 21 2007

Boston Brussels Chicago Düsseldorf London Los Angeles Miami Milan
Munich New York Orange County Rome San Diego Silicon Valley Washington, D.C.

FACSIMILE

Date: June 21, 2007

**Time
Sent:**

To:	Company:	Facsimile No:	Telephone No:
Mail Stop: AMENDMENT	USPTO	571-273-8300	
From:	Atabak R. Royaee	Direct Phone:	617.535.4108
E-Mail:	aroyaee@mwe.com		
Sent By:		Direct Phone:	
Client/Matter/Tkpr:	068911-0116	Original to Follow by Mail	No
		Number of Pages, Including Cover:	8

Message:

BST99 1525996-1.068911.0060

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copy of this facsimile is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the below address by mail. Thank you.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL AS SOON AS POSSIBLE.

Main Facsimile: 617.535.3800 Facsimile Operator: 617.535.4000

U.S. practice conducted through McDermott Will & Emery

60 State Street Boston, Massachusetts 02100-1775 Telephone: 617.535.4000

PAGE 1/8 * RCVD AT 6/21/2007 3:09:31 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-2/5 * DNIS:2738300 * CSID:617 535 3869 * DURATION (mm:ss):02-28

JUN 21 2007


PATENT
Attorney Docket No. 068911-0116IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tripp, et al.
 Application No.: 10/532,388
 Filing Date: April 21, 2005
 Docket Number: 068911-0116
 Title: COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL
 CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE
 Examiner: Not yet assigned
 Art Unit: 2616
 Confirmation No.: 1774

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Mail Stop: Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571) 273-8300 to the USPTO, on the date indicated below.

Date: June 21, 2007


 Jacqueline I. Andreu

MAIL STOP AMENDMENT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:


Enclosed herewith for filing in connection with the above-identified patent application are the following:

- 1) Second Preliminary Amendment (6 pages)

There are no fees believed to be due with the filing of this Second Preliminary Amendment. However, the Commissioner is authorized to charge any further fees which may become due and/or credit any overpayment to Deposit Account Number 50-1133.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Atabak R. Royaee, Reg. No. 59,037
 McDERMOTT WILL & EMERY LLP
 28 State Street
 Boston, Massachusetts 02109
 Telephone: (617) 535-4049
 Facsimile: (617) 535-3800

Dated: June 21, 2007

BST99 1540476-1.068911.0116

JUN 21 2007

PATENT
Attorney Docket No. 068911-0116


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
M. Tripp, et al.) Group Art Unit: 2616
Application No.: 10/532,388)
Examiner: Not Yet Assigned
Filed: April 21, 2005)
International Filing Date: October 20, 2003) Confirmation No.: 1774
)
For: Compositions that Treat or Inhibit
Pathological Conditions Associated
with Inflammatory Response

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted (571-273-8300) to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Date: June 21, 2007


Jacqueline J. Andreu

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application for a second time as follows:

Amendments to the Claims are reflected in the listing of claims in this paper at page 2.

Remarks/Arguments follow the amendment sections of this paper at page 6.